Zenarestat Chemische Eigenschaften,Einsatz,Produktion Methoden

Originator

FK 366 ,Fujisawa Pharmaceutical

Verwenden

Treatment of diabetic neuropathy (aldose reductase inhibitor).

Therapeutic Function

Aldose reductase inhibitor

Zenarestat Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Zenarestat Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49979	58
Hangzhou MolCore BioPharmatech Co.,Ltd.	+86-057181025280; +8617767106207	sales@molcore.com	China	49734	58
TargetMol Chemicals Inc.	+1-781-999-5354;	support@targetmol.com	United States	39037	58
TargetMol Chemicals Inc.	+17819995354	marketing@targetmol.com	United States	19956	58
Jingmo (Xiamen) Biotechnology Co., Ltd	13621943973; 13621943973	sales@jamxmpharmatech.com	China	1184	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11972	58
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	29867	58
Merck KGaA	--	ordercn@merckgroup.com	China	6394	58

---

• 3-(2-Fluoro-4-bromobenzyl)-7-chloro-2,4(1H,3H)-dioxoquinazoline-1-acetic acid
• 3-[(4-Bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid
• Zenarestat
• FR 74366
• 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid
• [3-(4-Bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydro-1(2H)- quinazolinyl]acetic acid
• 1(2H)-Quinazolineacetic acid, 3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-
• CI1014
• CI-1014
• FK-366
• 112733-06-9
• C17H11BrClFN2O4